NCT06714149

Brief Summary

The investigators want to study the effect of environmental nitrogen enrichment on the allergy burden in pollen-sensitized subjects.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 29, 2022

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

November 20, 2024

Completed
13 days until next milestone

First Posted

Study publicly available on registry

December 3, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2025

Completed
Last Updated

December 3, 2024

Status Verified

December 1, 2024

Enrollment Period

2.6 years

First QC Date

November 20, 2024

Last Update Submit

December 2, 2024

Conditions

Keywords

NitrogenPollutionPollen allergy

Outcome Measures

Primary Outcomes (1)

  • Specific IgE reactivity (in-house developed) against environmental and experimental pollen samples

    The investigators want to measure and compare sIgE values (kUA/L) towards different pollen samples.

    From time of inclusion to 12 months

Secondary Outcomes (3)

  • Basophil degranulation with different amounts of pollen on fresh patient-derived basophils.

    From time of inclusion to 12 months

  • Overall intensity (quantitative) of IgE reactivity to pollen samples in a subset of patients.

    From time of inclusion to 12 months

  • IgE-mediated hyper- or hyporecognition of different fragments in the pollen samples (qualitative) in a subset of patients.

    From time of inclusion to 12 months

Other Outcomes (5)

  • Association of allergic rhinoconjunctivitis symptoms with reactivity to different pollen samples (TNSS)

    From time of inclusion to 12 months

  • Association of allergic rhinoconjunctivitis symptoms with reactivity to different pollen samples (VAS)

    From time of inclusion to 12 months

  • Association of allergic rhinoconjunctivitis symptoms with reactivity to different pollen samples (PFS)

    From time of inclusion to 12 months

  • +2 more other outcomes

Study Arms (2)

Allergic subjects

OTHER

All subject with positive skin prick testing for grass and/or birch pollen are assigned to this group.

Diagnostic Test: Immunoreactivity testing

Healthy controls

OTHER

Subjects with negative skin prick testing for grass and/or birch pollen are assigned to this group and used for as negative controls in our experiments.

Diagnostic Test: Immunoreactivity testing (negative control)

Interventions

Blood samples will be collected and used to determine the intensity of the allergenicity of the subject toward different types of pollen. This will be done by the detection of sIgE antibodies to the pollen extracts and basophil activation testing (BAT) with pollen extracts.

Allergic subjects

Blood samples will be collected and used to determine the background activity of our immunoreactivity tests. The investigators will use samples from negative controls to demonstrate that non-allergic individuals do not react to our assays, confirming that our pollen extracts have no background reactivity. This will be done by the detection of sIgE antibodies to the pollen extracts and basophil activation testing (BAT) with pollen extracts.

Healthy controls

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Positive skin prick test for grass and/or birch pollen

You may not qualify if:

  • Desensitization therapy during the last two years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospitals Leuven

Leuven, Vlaams-Brabant, 3000, Belgium

RECRUITING

Related Publications (2)

  • Verscheure P, Honnay O, Speybroeck N, Daelemans R, Bruffaerts N, Devleesschauwer B, Ceulemans T, Van Gerven L, Aerts R, Schrijvers R. Impact of environmental nitrogen pollution on pollen allergy: A scoping review. Sci Total Environ. 2023 Oct 1;893:164801. doi: 10.1016/j.scitotenv.2023.164801. Epub 2023 Jun 14.

    PMID: 37321510BACKGROUND
  • Ceulemans T, Verscheure P, Shadouh C, Van Acker K, Devleesschauwer B, Linard C, Dendoncker N, Speybroeck N, Bruffaerts N, Honnay O, Schrijvers R, Aerts R. Environmental degradation and the increasing burden of allergic disease: The need to determine the impact of nitrogen pollution. Front Allergy. 2023 Feb 2;4:1063982. doi: 10.3389/falgy.2023.1063982. eCollection 2023. No abstract available.

    PMID: 36819832BACKGROUND

MeSH Terms

Conditions

Rhinitis, Allergic, Seasonal

Condition Hierarchy (Ancestors)

Rhinitis, AllergicRhinitisNose DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityOtorhinolaryngologic DiseasesHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Central Study Contacts

Rik Schrijvers, MD, PhD

CONTACT

Raf Aerts, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: A Cross-Sectional Paired Comparison Study
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Prof. dr.

Study Record Dates

First Submitted

November 20, 2024

First Posted

December 3, 2024

Study Start

June 29, 2022

Primary Completion

February 1, 2025

Study Completion

April 1, 2025

Last Updated

December 3, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Locations